Back

Impact of clopidogrel metabolizer status on platelet aggregation and association with outcomes in AF patients undergoing PCI

30 August 2025 (12:30 - 13:15)
Organised by: Logo
Congress Presentation Part of: New perspectives in cardiology (2) - Antithrombotic pharmacotherapy Antiplatelet Drugs ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Mrs Diona Gjermeni

Stanford Center for Clinical Research, Stanford (United States of America)

9 More presentations in this session

Presentation thumbnail
Presentation thumbnail
Mr G. Arrighini (Bologna, IT)
Abstract Slides Video
Presentation thumbnail
Doctor G. Occhipinti (Barcelona, ES)
Abstract Slides Video
Presentation thumbnail
Doctor M. Thungthienthong (Bangkok, TH)
Abstract Slides Video
Presentation thumbnail
Doctor M. Galli (Rome, IT)
Abstract Slides Video

Access the full session

Session thumbnail
New perspectives in cardiology (2) - Antithrombotic pharmacotherapy

The Event

Event poster

ESC Congress 2025

30 August 2025 12:30 CET
You may be interested in
thumbnail
Congress Presentation
Oral anticoagulation monotherapy versus combination antithrombotic therapy in patients with AF and PCI with a drug-eluting stent implantation: a systematic review and meta-analysis
thumbnail
Congress Presentation
Optimizing post-PCI therapy: ticagrelor, prasugrel, clopidogrel, and cilostazol reduce early MACE
thumbnail
Congress Presentation
Clinical impact of high platelet reactivity in patients with atrial fibrillation and concomitant percutaneous coronary intervention on dual or triple antithrombotic therapy

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources